益气养阴、活血化瘀法对病毒性心肌疾病小鼠心肌Fas、FasL蛋白表达的研究
|
摘要
目的:采用对Balb/c小鼠反复腹腔注射CVB_(3m)病毒的方法,复制病毒性心肌疾病模型,观察益气养阴,活血化瘀法对病毒性心肌疾病小鼠心肌Fas、FasL蛋白表达水平的影响,从细胞水平来探讨其作用机制,并为中药复方防治病毒性心肌疾病提供依据。
方法:将210只Balb/c小鼠,随机分为4组,空白对照组30只,模型对照组、中药高剂量组、中药低剂量组各60只。采用反复腹腔注射CVB_(3m)病毒的方法复制病毒性心肌疾病模型。常规方法观测小鼠心脏质量指数变化;采用HE、VG染色法观察各组心肌病理形态、心肌胶原组织及超微结构的变化;采用免疫组化法检测Fas、FasL蛋白表达。
结果:1.与空白对照组相比模型对照组、中药高、低剂量组小鼠心脏重量/体重比值均明显增高(P＜0.05);与模型对照组相比,中药高剂量组、中药低剂量组小鼠心脏重量/体重比值均明显降低(P＜0.05)。
2.与空白对照组相比模型对照组、中药高、低剂量组小鼠心肌病理形态及超微结构异常;与模型对照组比较中药高、低剂量组均有不同程度的减低。
3.与空白对照组比较模型对照组、中药高、低剂量组心肌组织内均有不同程度Fas、FasL蛋白的表达;与模型对照组比较中药高、低剂量组阳性表达明显降低(P＜0.05),中药高剂量组与中药低剂量组间无显著差异(P＞0.05)。
结论:Balb/c小鼠反复腹腔注射CVB_(3m)病毒的方法能成功的复制病毒性心肌疾病模型,以益气养阴、活血化瘀法组成中药复方能改善其心脏质量指数和病理形态学及超微结构的变化,并能够下调病毒性心肌疾病小鼠Fas、FasL蛋白表达,这可能是益气养阴、活血化瘀法组成中药复方防治病毒性心肌肌病的作用机制之一。
Objective:To investigate the effect of the method of yi qi yang yin huo xue hua yu on the rat model of viral myocardial disease by observing the expression of Fas/FasL protein in cardiac muscle.
Methods:Replicated the animal models of the viral myocardial disease with the method of injecting the CVB_(3m)virus to the peritoneal cavity of the Balb/c rats for 6 times.210 Balb/c male rats were divided into 4 groups at random:blank group,model group,low dose traditional Chinese medicine group and high dose traditional Chinese medicine group.The blank group has 30 rats.The other three group has 60 rats each.Then observe the change of pathomorphology in the cardiac muscle tissue on the 90th day of the experiment.And immunohistochemistry method was used to exam the expression of Fas/FasL protein in cardiac muscle.
Results:1.Compared with the blank group the cardiac weight index of the other three groups is higher,and compared with the model group the cardiac weight index of low dose and high dose traditional Chinese medicine group is lower.
2.Compared with the blank group the changes of the pathomorphismand and the ultra-structure in other three groups is abnormal.,and compared with the model group the changes of the pathomorphismand and the ultra-structure of low dose and high dose traditional Chinese medicine group is lower.
3.Compared with the blank group there are the expression of Fas/FasL protein in every other group's cardiac muscle,and compared with the model group the expression of Fas/FasL protein in cardiac muscle in the low dose and high dose traditional Chinese medicine group is lower.
Conclusions:
1.The prescription on the base of the method of yiqiyangyinhuoxuehuayu can lower the cardiac weight index and lower the changes of the pathomorphismand and the ultra-structure in cardiac muscle.The prescription can reduce the expression of Fas/ FasL protein in cardiac muscle that maybe cure viral myocardial disease.
方法:将210只Balb/c小鼠,随机分为4组,空白对照组30只,模型对照组、中药高剂量组、中药低剂量组各60只。采用反复腹腔注射CVB_(3m)病毒的方法复制病毒性心肌疾病模型。常规方法观测小鼠心脏质量指数变化;采用HE、VG染色法观察各组心肌病理形态、心肌胶原组织及超微结构的变化;采用免疫组化法检测Fas、FasL蛋白表达。
结果:1.与空白对照组相比模型对照组、中药高、低剂量组小鼠心脏重量/体重比值均明显增高(P＜0.05);与模型对照组相比,中药高剂量组、中药低剂量组小鼠心脏重量/体重比值均明显降低(P＜0.05)。
2.与空白对照组相比模型对照组、中药高、低剂量组小鼠心肌病理形态及超微结构异常;与模型对照组比较中药高、低剂量组均有不同程度的减低。
3.与空白对照组比较模型对照组、中药高、低剂量组心肌组织内均有不同程度Fas、FasL蛋白的表达;与模型对照组比较中药高、低剂量组阳性表达明显降低(P＜0.05),中药高剂量组与中药低剂量组间无显著差异(P＞0.05)。
结论:Balb/c小鼠反复腹腔注射CVB_(3m)病毒的方法能成功的复制病毒性心肌疾病模型,以益气养阴、活血化瘀法组成中药复方能改善其心脏质量指数和病理形态学及超微结构的变化,并能够下调病毒性心肌疾病小鼠Fas、FasL蛋白表达,这可能是益气养阴、活血化瘀法组成中药复方防治病毒性心肌肌病的作用机制之一。
Objective:To investigate the effect of the method of yi qi yang yin huo xue hua yu on the rat model of viral myocardial disease by observing the expression of Fas/FasL protein in cardiac muscle.
Methods:Replicated the animal models of the viral myocardial disease with the method of injecting the CVB_(3m)virus to the peritoneal cavity of the Balb/c rats for 6 times.210 Balb/c male rats were divided into 4 groups at random:blank group,model group,low dose traditional Chinese medicine group and high dose traditional Chinese medicine group.The blank group has 30 rats.The other three group has 60 rats each.Then observe the change of pathomorphology in the cardiac muscle tissue on the 90th day of the experiment.And immunohistochemistry method was used to exam the expression of Fas/FasL protein in cardiac muscle.
Results:1.Compared with the blank group the cardiac weight index of the other three groups is higher,and compared with the model group the cardiac weight index of low dose and high dose traditional Chinese medicine group is lower.
2.Compared with the blank group the changes of the pathomorphismand and the ultra-structure in other three groups is abnormal.,and compared with the model group the changes of the pathomorphismand and the ultra-structure of low dose and high dose traditional Chinese medicine group is lower.
3.Compared with the blank group there are the expression of Fas/FasL protein in every other group's cardiac muscle,and compared with the model group the expression of Fas/FasL protein in cardiac muscle in the low dose and high dose traditional Chinese medicine group is lower.
Conclusions:
1.The prescription on the base of the method of yiqiyangyinhuoxuehuayu can lower the cardiac weight index and lower the changes of the pathomorphismand and the ultra-structure in cardiac muscle.The prescription can reduce the expression of Fas/ FasL protein in cardiac muscle that maybe cure viral myocardial disease.
引文
1 Caforio AL,BaboonianC,Mc Kenna WJ.Postviral autoimmune heartdisease-fact or fiction.Eur Heart J,1997,18:1051-1055
2 Tracy S,Chapman NM,Romero J.et al Genetics of CoxsackievirusB cardiovirulence and inflammatory heart muscle disease.[J] Trends Microbil,1996,4:175-179
3 Bowles NE,Richardson PJ,Olsen EGJ,et al. Detection of coxsack-ie B virus specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy[J].Lancet,1986,1:1120-1123
4 Bowles NE,Rose ML,Taylor P,et al.End-stage dilated cardiomy-opathy persistence of. Enter ovirus RNA in myocardium at cardiac transplantation and lack of immune response[J]. Circulation, 1989,80:1128-1136
5 JinO,Sole MJ,Butanny JW,et al. Detection of enterovirus RNA in myocardial biopsy from patients with myocarditis and myocardiopa-thy using gene anplification by polymerase chain reaction[J]. Circulat-ion, 1990, 82(1):8-16
6 Pauschinger M, Bowles NE, Fuentes-Carcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiop-athic left ventricular dysfunction[J]. Circulation ,1999, 99:1384-1354
7 Kyu BS, Matsumori A, Sato Y, et al. Cardiac persistence of cardi-oviaral RNA detected by polymerase chain reaction in a murine m-odel of dilated cardiomy-pathy[J].Circulation,1992, 86(2):522-530
8 TamPE,etal.JVirol,1999;73(12):10113-10121
9 ConaldiPG,etal.JInfectDis,1997;175:693-696
10 KlingelK,etal.ProcNatlAcadSciUSA,1992;89:314-318)
11 WesselyR,etal.Circulation,1998;4;98(5):450-457
12 KandolfR,etal.VirusResearch,1999;62:149-158
13 KlingelK,etal.JVirol,1996;70(12):8888-8895
14 Schnurr DP,et al.Arch Virol, 1984;81:91-101
15 Tonew M, et al. Zentraibl Bakteriol, 1995; 282(1):92-101)
16 YamamuraT,NakamuraH,Yamama-toT,etal.Fasexpressionandapop-tosiscorrelatedwithcardiacd ysfunc-tioninpatientswithdilatedcardiomy-opath[J].JpnCircJ, 1999,63(3): 149-154.
17 YmaguchiS,YamaokaM,OkuyamaM,etal.Elevatedcirculationlevelsandcardiacsecretionofsolubl eFasligandinpatientswithcongestiveheartfailure[J].AmJCardiol, 1999,83(10): 1500-1503.
18 Martin R Bennett. Apoptosis in the cardiovascular system.Heart 2002;87:480-487
19 W.R oobb Maclellan,Michael D.Schneider.Programmed cell death in cardiovascular biology and disease.Circulation Research-Maclellan and Scheneider 1997 Aug 81(2):137-144
20 Armin Haunstetter,Seigo Izumo.Apoptosis basic mechanisms and implications for cardiovascular ddisease.Circulation Research.1998,82:1111-1129.
21 Geng yong jian.Molecular signal transduction in vascular cell apoptosis.Cell Research.2001,11(4):256-264
22 Maianski NA,Mul FP,van BuulJD,et al.Granulocyte colony-stimulating factorlnhibits the mitochondria-dependent activation of caspase-3in neutrophils.Blood.2002;99:672-9
23 Otsuki T,Miura Y,Nishimura Y,et al.Aletrations of fas and fas-relatedMolecules in patients wih silieosis.Exp Biol Med(Maywood).2006Mya:231(5):522-33
24 Perez EC,Shulzhenko N,Morgun A,et al.Expression of Fas,FasL,and Soluble Fas mRNA in Endomyocardial Biposies of Human Cardiac Allografts.Hum Immunol.2006Jna-Feb:67(1-2):22-6
25 Gomez L,Chavanis N,Argaud L,et al.Fas-independent mitochondrial damage Trtiggers cardiomyocyte death after ischmeia-reperfusion.Am J Physiol Heart CircPhysiol.2005Nov;289(5):H2153-8.
26 KawanoH,OkadaR,kawano Y,etal.Apoptosisinacuteandchyonicmyocarditis[J].JpnHeartJ,1994,35(6):745-750
27 Toyozaki T,H iroe M,Tanaka M.L e2vels of solubie Fas ligand in m y2ocarditis[J].Am J Cardio,1998,82(2):2462248
28 韩波,马沛然,刘芳,等.细胞凋亡和FasFasL基因在小鼠病毒性心肌炎发病中的作用[J].中华儿科杂志,2000,38(7):405-408
29 王仑宋,晓东病毒性心肌炎心肌细胞凋亡机制研究 中国分子心脏病学杂志 2003年10月第3卷第5期
30 Rao I,Debbas M,Sabbatini P,et al.The asenovirus EIA proteins induce apoptosis,which is snhibited by the EIB19-kDa and Bcl-2 proteins.Proc Natl Acad Sci USA.1992;89:7742-7746
31 Gang Y,Smith G,et al Familial dilated cardicm yopathy in the United kindom.Br H.Keeling eart J,1995,73:417-721
32 Abelmann WH,Lorbell BH,The challenge of cardiom yopathy.J Am Coll Cardiil,1989,13:1209-1223
33 Gauntt GJ.Role of the humoral response in coxsackievirus B in-duced disease[J].Curr Top Microbiol Immunol,1997,223:259-283
34 Schwimmbeck PL,Badorff C,Rohn G,et al.The role of sensited T-cells in myocard-itisanddialtedcardiomyopathy[J].IntJourofCardiology,1996(54):117-125
35 Binah O.Pharmacologic modulation of the immune interaction between cytotoxiclym phocytes and ventricular myocytes[J].J Cardiovasc Pharmacol,2001,38(2):298 316
36 Takemoto M,Kusachi S,Urabe N,et al.Auto-antibody against myocaritis incidence and relation to cardiac function and morphology[J].Japanese Circulation Journal,1993,57(12):1150-1158
37 Liao YH,Functional analysis of autoantibodies against ADP/ATP carrier from dilated cardiomyopathy[J].International Journal of Ca-rdiology,1996,54(2):165-169
38 Wallukat G,Reinke P,Dorffel WV,et al.Removal of autoantibod-ies in dilated cardiomyopathy by immunoadsorption[J].International Journal of Cardiology,1996,54:191-195
39 Liang Xiong F,Yvonne M,Claes Hakan B,et al.Localization of a functional autoimmune epitope on the muscarinic acetylcho linerecepter 2 in the patients with idiopathic dilated cardiomyopat-hy[J].J Clin Invest,1993,91:1964-1968
40 Yvonne M,Stefano M,Soren H,et al.Mapping of a functional autoimmu-ne epitope on the β_1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy[J].J Clin Invest,1990,86:1658-1663
41 宋振玉,刘耕陶,主编.当代药理学[M].北京:北京医科大学、中国协和医科大学联合出版社出版,1994,29:44
42 Magnusson Y,Wallukat G,Waagstein F,et al.Autoimmunity in idiopathic dilated cardiomyopathy:characterizatin of antibod-ies against the β_1 adrenoceptor with positive chronotropi effect[J].Cireulation,1994,89:2760-2767
43 Wang Z,Liao Y,Dong J,et al.Clinical significance and patho-genic role of anticardiac myosin autoantibody in dilated cardio-myopathy[J].Chin Med J(Engl),2003,116(4):499-502
44 王玉亭.扩张型心肌病发病机理及治疗进展[J].中国心血管杂志,2005,10.231.)
45 AzumaA,MatsuoA,NakamuraT,et al lm prored Survial of id iopathic dilated,cardiomyopathy,in the 1990s[J].Jpneircj,1999,63,333-338)
46 Archard LC,Bowles NE,Cunningham L,et al.Molecular probes for detection of persisting enteroviarl infection of human heart and their prognostic value[J].Eur Heart J,1991,12(suppl D):56-59
47 Why HJF,Meany BT,Richardson PJ,et al.Clinical and prognostic significance of detecion of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy[J].Circulation,1994,89:2582-2589
48 CiceG,FerraraL,diBenedettoA,etal.Dilatedcardiomyopathyindialysispatients2beneficialeffects of carvedilol:adouble2blind,placebo2controlledtrial[J].J Am CollCardiol,2001,37(2):4072411
49 CiceG,FerraraLD,A ndreaA,etal.Carvedilolincreasetwo2yearsurvivalindialysispatientswithdilat edcardiomyopathy:aprospective,placebo2controlledtrial[J].J AmCollCardiol,2003,41(9):143821444
50 MatsumuraST,TsushimaK,OhtakiE,etal.EffectsofcarvedilolonplasmalevelsoflL26andTNF2Ain ninepatientswithdilatedcardiomyopathy[J].J Cardiol,2002,39(5):2532257.)
51 OhtsukaT,HamadaM,SaekiH,etal.Comparisonofeffectsofcarvedilolversusmetoprololoncytokin elevelsinpatientswithidiopathicdilatedcardiomyopathy[J].AmJCardiol,2002,89(8):9962999.
52 LowesBD,GilbertEM,AbrahamWT,etal.Myocardialgeneindilatedcardiomyopa2thytreatedwithb eta2blockingagents[J].NewEnglJMed,2002,346(18):-135721365.
53 苑海涛,廖玉华,王敏,等.系列抗心肌多肽抗体对扩张型心肌病的诊断价值[J].临床心血管病杂志,2000,16:31-315
54 程龙献,廖玉华,涂源淑,等.扩张型心肌病者血清抗ADP/ATP载体抗体对心肌细胞浆游离钙浓度的影响[J].临床心血管病杂志,1996,11:335-337
55 OsterzielKJ,RankeMB,StrohhmO,etal.Thesomatotrophicsysteminpatientswitdilatedcardiomyop athy:relationofinsulin21ikegrowthfactor21 anditsalterationsdur2inggrowthhorrnonetherapytoc ardiacfunction[J].ClinEndocri,2000,53(1):61268
56 Perrot A,RankeMB,DietzR,etal.Growthhormonetreatrnentindilatedcardiomy2opathy[J].JCardia cSurg,2001,16(2):1272131
57 Jose VJ,ZechariahTU,GeorgeP,etal.Growthhormonetherapyinpatientswithdilatedcardiomyopath y:prelirninaryobservationsofapilotstudy[J].Indi2anHeartJ,1999,51(2):1832185
58 LindeC,lederoqC,Rexs,et aj Long-term benefits of biventricular pacing in congestive heart failure results from the rnultisite stirnulation in cardiorn yopa thy study[J],J Am Coll Cardiol,2002,40(1):111-118
59 EtochS W,C erit oP,HenahanB J,etal.Intermediate 2termresultsafterpartialleftven2triculectomyfor end2stagedilatedcardiomyopathy:isthereasurvivalbenefit?[J].J Cardiac Surg,2001,16(2):1532158
60 DoenstT,Ahn2VeelkenL,SchlensakC,etal.Leftventricularreductionforidiopathdilatedcardiomyo athyasalternativetotransplant2truthordare[J]? ThoracicCadiovascSurg,2001,49(2):70274
61 马鸿斌.曹玉山治疗扩张型心肌病经验[J].中医研究,2000,13(6):6
62 秦国昌.扩张性心肌病治疗报告[J].中国医药学报,1992,(3):32
63 吕承全.樟木生脉饮治疗扩张性心肌病[J].中医研究,1994,(3):25
64 骆丰,邵念方.保丹生脉汤治疗扩张型心肌病心衰30例[J].江苏中医,1997,18(11): 14
65 程继昆,刘庆平.中药治疗扩张型心肌病25例[J].吉林中医药2002,22(1):12
66 郭占军,刘军峰.中西医结合治疗扩张型心肌病6例报道[J].陕西中医学院学报,2002,25(5):19-20
67 郭喜军,王芩,王英.生脉心肌汤治疗扩张型心肌病临床观察[J].北京中医药大学学报,2003,26(1):79
68 商发科.中西医结合治疗扩张型心肌病疗效观察[J].中国中医急症,2003,12(4):300
69 徐伟建,王汉祥,张道亮,等.中西医治疗扩张型心肌病疗效分析[J].上海中医药杂志,2000,11:12-13
70 柳新.运用温阳益气法治疗扩张型心肌病的体会[J].北京中医,2000,4:29
71 吴新欲,陆曙,龚少愚,等.心力神治疗扩张型心肌病的临床观察[J].新中医,2001,33(3):20-21
72 梁贵廷,刘真,于慧卿,等.活力心浓缩水丸治疗扩张型心肌病临床研究[J].河北中医,2002,24(12):883-886
73 柳新,靳军,张勇.自拟温阳益气汤治疗扩张型心肌病86例观察[J].Beijing jouralof TCM,2004,23(6):348
74 史小青,官颖.温阳利水治疗扩张型心脏病心衰32例[J].辽宁中医杂志,2002,29(5):272
75 曾锋自.拟虚里安汤合三联疗法治疗扩张型心肌病心衰32例[J].中国中医药信息杂志,2003,10(7):51
76 肖少寒,邓斌,陈芸,等.中西医结合治疗扩张型心肌病46例临床观察[J].现代医药卫生,2005,21(18):2424-2425
77 田友谊.中药自拟方治疗扩张型心脏病的临床研究[J].Chinese Journal of information on TCM,2005,12(7):54
78 王树炜.心肌复原散治疗扩张型心肌病40例疗效观察[J].四川中医,2004,22(2):48
79 廖蔚茜,房莉萍,丛鹏.益气活血法治疗扩张型心肌病临床观察[J].上海中医药杂志,2005,39(5):临证承启19
80 关德民,张春燕.温阳利水法为主治疗慢性充血性心力衰竭60例[J].中医药学报,2002,30(3):11
81 贺又舜,伍参荣,赵国荣,等.甘露消毒丹对柯萨奇病毒体外抑制作用的实验研究[J].中国中西医结合杂志,1998,18(12):737-740.
82 陈万强,薛成相,马慧,等.中西医结合治疗扩张型心脏病疗效观察[J].西北国防医学杂志,1999,20(4):286-287
83 郑红发.独参汤治疗扩张型心肌病20例疗效观察[J].中国临床药理学与治疗学杂志, 1997,2(1):12
84 刘吉祥,张金艳,冯丽娟,等.中西医结合治疗扩张型心肌病86例临床观察[J].中国新医药,2004,3(3):53-54
85 白玉生,杨晓华,周艳萍.中西医结合治疗扩张型心肌病疗效观察.中西医结合实用临床急救,1997,4(5):216-217
86 梁东勇.加味生脉散配合西药治疗扩张型心肌病30例[J].四川中医,2002,20(4):29-30
87 王西栋,张广兰,梁玉梅,等.小柴胡汤对病毒性心肌炎动物模型治疗作用的实验研究[J].中国中药杂志,1997,22(11):684-686.
88 王雪峰,刘芳,魏克伦,等.小柴胡汤及其分解剂对柯萨奇B3m病毒感染乳鼠心肌保护及细胞免疫调节作用的研究[J].中国中西医结合杂志,2000,20(8):599-602.
89 蒋岩,崔小岱,吴莎,等.红芪提取物(HE)亲心肌柯萨奇B3病毒(CVB3m)感染的作用初探[J].医学研究通讯,1994,23(5):15-18.
90 吴伟忠,杨英珍,金佩英.黄芪对BALb/c小鼠Coxsackie B3病毒T细胞免疫的影响[J].中国病毒学,1992,7(2):129-132.
91 芮涛,杨英珍,杨学义,等.黄芪对小鼠急性病毒性心肌炎作用的心肌细胞电生理研究[J].中国中西医结合杂志,1994,14(5):292-294.
92 郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1995,15(8):483-485.
93 李双杰,张召才,陈瑞珍,等.黄芪甲甙治疗BALB/C小鼠CVB3病毒性心肌炎疗效研究[J].中华实用中西医结合杂志,2004,4(5):681-683.
94 刘晶星,陆德源,杨仲明.苦参抗柯萨奇B组病毒的初步研究[J].上海第二医科大学学报,1991,11(2):140-142.
95 陈福祥,刘晶星,陆德源.苦参总碱体外抗柯萨奇病毒B型3作用测定及其机理的初步研究[J].中华实验和临床病毒学杂志,1995,9(2):115-117.
96 孙非,王秀清,李静波.高山红景天多糖抗柯萨奇B5病毒作用的研究[J].中草药,1993,24(10):532-534.
97 孙非,于起福,孙寒,等.高山红景天多糖对病毒感染大鼠心肌细胞的抑制作用[J].中国药理学通报,1997,13(6):525-528.
98 朱理安.实验性病毒性心肌炎药物治疗及凋亡的机制[J].福建医科大学学报,1998,32(9):318.
99 蒋岩,包天桐,崔小岱,等.薄芝醇提取物体外抗亲心肌柯萨奇B3病毒作用的研究[J].北京中医,1994,(3):31-32.
100 申元英,杨占秋,刘建军,等.大黄在体内抗柯萨奇病毒B3的实验研究[J].中国病毒学, 2001,16(1):85-87.
101 申成华,郑善子,崔春权,等.虎杖水煎液对体外培养柯萨奇病毒B3大鼠心肌细胞保护作用的实验研究[J].中国中医药科技,2005,12(1):34-35.
102 董杰德,陈晨华,仇素英,等.四种中草药抗柯萨奇及埃柯病毒的实验研究[J].山东中医学院学报,1993,17(4):46-48.
103 郑敏,菜飞,吴基良,等.大蒜多醣抗柯萨奇病毒B3及病毒性心肌炎实验研究[J].中华实用中西医结合杂志,2004,4(11):1 577-1579.
104 秦勇,黄方文,王金宇.999参附注射液治疗扩张型心肌病心力衰竭26例[J].辽宁中医杂志,2001,28(7):407
105 阙华星,郭建辉.参附注射液治疗扩张型心肌病32例[J].福建中医药,2003,34(2):17
106 张荣江,安立敏,张连娟,等.参麦注射液与维生素C注射液辅助治疗扩张型心肌病的疗效比较[J].中国新药与临床杂志,2001,20(3):190-192
107 李世光,张启高.参麦注射液治疗扩张型心肌病合并左心功能不全临床观察[J].安徽医药,2002,6(2):27
108 吴新华,焦建玲,施荣杰.生脉注射液辅助治疗扩张型心肌病心力衰竭28例[J].中国中西医结合杂志,200l,21(3):230
109 张亚臣,陈瑞明,赵美华,等.生脉注射液治疗扩张型心肌病心力衰竭的疗效观察[J].临床内科杂志,2002,19(增刊):102-104
110 张兰芹.黄芪和生脉注射液联用治疗扩张型心肌病33例[J].天津中医药,2003,20(2):29
111 徐占兴.复方丹参注射液治疗扩张型心肌病22例疗效分析[J].天津中医药,2003,20(2):74
112 杨桂生.联用当归注射液和复方丹参注射液治疗扩张型心肌病5例[J].中西医结合实用临床急救,1998,5(9):425
113 陈曙霞,包世宏,常佩伦.针刺内关及少府对原发性心肌病心脏效应的初步探索[J].中医杂志,1982,23(8):4852
114 陈曙霞,谢龙山,马睿,等.柯萨奇B病毒性心肌炎、扩张型心肌病中病毒持续感染及中药干预的实验研究[J].中西医结合心脑血管病杂志,2003,1(3):129-131
115 徐伟建,张道亮,李颖,等.保心合剂对CVB3病毒致小鼠慢性心肌损伤的保护作用[J].中西医结合心脑血管病杂志,2006,4(1):39-41
116 Brilla CG,Janick JS,Weber KT.Impaired diastolic function and coronary reserve in genetic hypertension[J].CircRes,1991,69(1):107-109
117 Papoinan T,Lewis W.Selective alterations in rat cardiac mRNA induced bydoxo.rubicin:possiblesubcellular mechanisms.Exp Mol Pathol.1991Apr:54(2):112-21
118 Power JM,Raman J,Byme MJ,et ql.Efficacy of the Acorn Cardiac Support Device in animals with failure secondary to high rate pacing.Heart Fail Rev.2005Jun;10(2):117-23
119 Takagaki M,Meearthy PM,Tobata T,et al.Induction and maintenance of an experimental model of severe cardiomyopathy with a novel protocol of rapid ventricular pacing.J Thorac Cardiomyopa thy with a novel protocol of rapid ventricular pacing.J Thorac Cardiovasc Surg,2002,123(3):544-549
120 McMinn TR,Ross J.Hereditary dilated cardiomyopathy.Clin Cardiol,1998,18(1):7-15
121 TsutamotoT,Wada A,Sakai H,et al.Relationship between renal function and plasma brain natriuretic peptide in patients with heart filure.J Am Coll Cardiol.2006Fbe7;47(3):582-6
122 Ikeda Y,Ross J Models of dilated cardiomyopathy in the mouse and the hamsrer.Curt Opin Cardiol,2000,15(3):197-201
123 Tracy S,Chapman NM,Romero J,et.Genetics of Coxsackievirus B cardioviru-lence and inflammatory heart muscle disease[J].Trends Micr0bil,1996,4:175-179
124 石迪明,陈曙霞,钱福荣,等.扩张型心肌病与病毒持续感染关系的实验研究[J].上海第二医科大学学报,2001,21(3):196-198
125 徐伟建,张道亮,李颖,等.保心合剂对CVB_3病毒致小鼠慢性心肌损伤的保护作用[J].中西医结合心脑血管病杂志,2006,4(1):39-41
126 郭玲,王莹威,孙辉,等.CVB3m重复感染心肌致心室重构的实验研究[J].中国地方病防治杂志,2005,20(3):132-134
127 李双杰,张召才,陈瑞珍,等.Balb/c小鼠CVB3病毒性扩张型心肌病并心力衰竭模型的建立.复旦学报(医学版),2004,31(6):559-561
128 杨英珍,单越芬,赵惠扬,等.黄芪对病毒性心肌炎患者左心室功能的影响[J].上海医科大学学报,1989,16(2):87-91
129 罗海明,戴瑞鸿,李勇.黄芪有效成分治疗充血性心力衰竭的心脏病学研究[J].中国中西医结合杂志,1995,15(12):707-709
130 孙成文,钟国赣,江岩,等.黄芪多糖抗氧化损伤的研究[J].中国药理学通报,1996,12(2):161-163
131 施海明,戴瑞鸿,范维虎.利多卡因和黄芪对心室晚电位的干预作用[J].中国中西医结合杂志,1994,14(10):598-600
132 Guo q,Peng TQ,Yang YZ,et al.Effect of astragalus membranaceus on Ca~(2+)influx and CVB3RNA replication in cultured neonatal rat heart cells infected with CVB3[J].CJIM,1996,2:64-67
133 刘恭鑫,杨英珍,顾全保,等.黄芪对感染病毒大鼠心肌细胞L型离子通道的效应[J]. 中国中西医结合杂忐,1998,18:51-53
134 彭天庆,杨英珍.黄芪对柯萨奇B3病毒核糖核酸作用的研究及其机理探讨[J].中国中西医结合杂志,1994,14(11):664
135 李兰青.地黄药理研究进展[J].中成药,1994,6(9):47.
136 马健,樊巧玲,木村正康.生地黄对“阴虚”模型小鼠腹腔巨噬细胞Ia抗原表面的影响[J].中药药理与临床,1998,14(2):22-24.
137 阿部博子.地黄及八味地黄丸的药效药理[J].国外医学·中医中药分册,1992,14(2):18
138 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,259
139 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,120-121
140 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,259
2 Tracy S,Chapman NM,Romero J.et al Genetics of CoxsackievirusB cardiovirulence and inflammatory heart muscle disease.[J] Trends Microbil,1996,4:175-179
3 Bowles NE,Richardson PJ,Olsen EGJ,et al. Detection of coxsack-ie B virus specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy[J].Lancet,1986,1:1120-1123
4 Bowles NE,Rose ML,Taylor P,et al.End-stage dilated cardiomy-opathy persistence of. Enter ovirus RNA in myocardium at cardiac transplantation and lack of immune response[J]. Circulation, 1989,80:1128-1136
5 JinO,Sole MJ,Butanny JW,et al. Detection of enterovirus RNA in myocardial biopsy from patients with myocarditis and myocardiopa-thy using gene anplification by polymerase chain reaction[J]. Circulat-ion, 1990, 82(1):8-16
6 Pauschinger M, Bowles NE, Fuentes-Carcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiop-athic left ventricular dysfunction[J]. Circulation ,1999, 99:1384-1354
7 Kyu BS, Matsumori A, Sato Y, et al. Cardiac persistence of cardi-oviaral RNA detected by polymerase chain reaction in a murine m-odel of dilated cardiomy-pathy[J].Circulation,1992, 86(2):522-530
8 TamPE,etal.JVirol,1999;73(12):10113-10121
9 ConaldiPG,etal.JInfectDis,1997;175:693-696
10 KlingelK,etal.ProcNatlAcadSciUSA,1992;89:314-318)
11 WesselyR,etal.Circulation,1998;4;98(5):450-457
12 KandolfR,etal.VirusResearch,1999;62:149-158
13 KlingelK,etal.JVirol,1996;70(12):8888-8895
14 Schnurr DP,et al.Arch Virol, 1984;81:91-101
15 Tonew M, et al. Zentraibl Bakteriol, 1995; 282(1):92-101)
16 YamamuraT,NakamuraH,Yamama-toT,etal.Fasexpressionandapop-tosiscorrelatedwithcardiacd ysfunc-tioninpatientswithdilatedcardiomy-opath[J].JpnCircJ, 1999,63(3): 149-154.
17 YmaguchiS,YamaokaM,OkuyamaM,etal.Elevatedcirculationlevelsandcardiacsecretionofsolubl eFasligandinpatientswithcongestiveheartfailure[J].AmJCardiol, 1999,83(10): 1500-1503.
18 Martin R Bennett. Apoptosis in the cardiovascular system.Heart 2002;87:480-487
19 W.R oobb Maclellan,Michael D.Schneider.Programmed cell death in cardiovascular biology and disease.Circulation Research-Maclellan and Scheneider 1997 Aug 81(2):137-144
20 Armin Haunstetter,Seigo Izumo.Apoptosis basic mechanisms and implications for cardiovascular ddisease.Circulation Research.1998,82:1111-1129.
21 Geng yong jian.Molecular signal transduction in vascular cell apoptosis.Cell Research.2001,11(4):256-264
22 Maianski NA,Mul FP,van BuulJD,et al.Granulocyte colony-stimulating factorlnhibits the mitochondria-dependent activation of caspase-3in neutrophils.Blood.2002;99:672-9
23 Otsuki T,Miura Y,Nishimura Y,et al.Aletrations of fas and fas-relatedMolecules in patients wih silieosis.Exp Biol Med(Maywood).2006Mya:231(5):522-33
24 Perez EC,Shulzhenko N,Morgun A,et al.Expression of Fas,FasL,and Soluble Fas mRNA in Endomyocardial Biposies of Human Cardiac Allografts.Hum Immunol.2006Jna-Feb:67(1-2):22-6
25 Gomez L,Chavanis N,Argaud L,et al.Fas-independent mitochondrial damage Trtiggers cardiomyocyte death after ischmeia-reperfusion.Am J Physiol Heart CircPhysiol.2005Nov;289(5):H2153-8.
26 KawanoH,OkadaR,kawano Y,etal.Apoptosisinacuteandchyonicmyocarditis[J].JpnHeartJ,1994,35(6):745-750
27 Toyozaki T,H iroe M,Tanaka M.L e2vels of solubie Fas ligand in m y2ocarditis[J].Am J Cardio,1998,82(2):2462248
28 韩波,马沛然,刘芳,等.细胞凋亡和FasFasL基因在小鼠病毒性心肌炎发病中的作用[J].中华儿科杂志,2000,38(7):405-408
29 王仑宋,晓东病毒性心肌炎心肌细胞凋亡机制研究 中国分子心脏病学杂志 2003年10月第3卷第5期
30 Rao I,Debbas M,Sabbatini P,et al.The asenovirus EIA proteins induce apoptosis,which is snhibited by the EIB19-kDa and Bcl-2 proteins.Proc Natl Acad Sci USA.1992;89:7742-7746
31 Gang Y,Smith G,et al Familial dilated cardicm yopathy in the United kindom.Br H.Keeling eart J,1995,73:417-721
32 Abelmann WH,Lorbell BH,The challenge of cardiom yopathy.J Am Coll Cardiil,1989,13:1209-1223
33 Gauntt GJ.Role of the humoral response in coxsackievirus B in-duced disease[J].Curr Top Microbiol Immunol,1997,223:259-283
34 Schwimmbeck PL,Badorff C,Rohn G,et al.The role of sensited T-cells in myocard-itisanddialtedcardiomyopathy[J].IntJourofCardiology,1996(54):117-125
35 Binah O.Pharmacologic modulation of the immune interaction between cytotoxiclym phocytes and ventricular myocytes[J].J Cardiovasc Pharmacol,2001,38(2):298 316
36 Takemoto M,Kusachi S,Urabe N,et al.Auto-antibody against myocaritis incidence and relation to cardiac function and morphology[J].Japanese Circulation Journal,1993,57(12):1150-1158
37 Liao YH,Functional analysis of autoantibodies against ADP/ATP carrier from dilated cardiomyopathy[J].International Journal of Ca-rdiology,1996,54(2):165-169
38 Wallukat G,Reinke P,Dorffel WV,et al.Removal of autoantibod-ies in dilated cardiomyopathy by immunoadsorption[J].International Journal of Cardiology,1996,54:191-195
39 Liang Xiong F,Yvonne M,Claes Hakan B,et al.Localization of a functional autoimmune epitope on the muscarinic acetylcho linerecepter 2 in the patients with idiopathic dilated cardiomyopat-hy[J].J Clin Invest,1993,91:1964-1968
40 Yvonne M,Stefano M,Soren H,et al.Mapping of a functional autoimmu-ne epitope on the β_1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy[J].J Clin Invest,1990,86:1658-1663
41 宋振玉,刘耕陶,主编.当代药理学[M].北京:北京医科大学、中国协和医科大学联合出版社出版,1994,29:44
42 Magnusson Y,Wallukat G,Waagstein F,et al.Autoimmunity in idiopathic dilated cardiomyopathy:characterizatin of antibod-ies against the β_1 adrenoceptor with positive chronotropi effect[J].Cireulation,1994,89:2760-2767
43 Wang Z,Liao Y,Dong J,et al.Clinical significance and patho-genic role of anticardiac myosin autoantibody in dilated cardio-myopathy[J].Chin Med J(Engl),2003,116(4):499-502
44 王玉亭.扩张型心肌病发病机理及治疗进展[J].中国心血管杂志,2005,10.231.)
45 AzumaA,MatsuoA,NakamuraT,et al lm prored Survial of id iopathic dilated,cardiomyopathy,in the 1990s[J].Jpneircj,1999,63,333-338)
46 Archard LC,Bowles NE,Cunningham L,et al.Molecular probes for detection of persisting enteroviarl infection of human heart and their prognostic value[J].Eur Heart J,1991,12(suppl D):56-59
47 Why HJF,Meany BT,Richardson PJ,et al.Clinical and prognostic significance of detecion of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy[J].Circulation,1994,89:2582-2589
48 CiceG,FerraraL,diBenedettoA,etal.Dilatedcardiomyopathyindialysispatients2beneficialeffects of carvedilol:adouble2blind,placebo2controlledtrial[J].J Am CollCardiol,2001,37(2):4072411
49 CiceG,FerraraLD,A ndreaA,etal.Carvedilolincreasetwo2yearsurvivalindialysispatientswithdilat edcardiomyopathy:aprospective,placebo2controlledtrial[J].J AmCollCardiol,2003,41(9):143821444
50 MatsumuraST,TsushimaK,OhtakiE,etal.EffectsofcarvedilolonplasmalevelsoflL26andTNF2Ain ninepatientswithdilatedcardiomyopathy[J].J Cardiol,2002,39(5):2532257.)
51 OhtsukaT,HamadaM,SaekiH,etal.Comparisonofeffectsofcarvedilolversusmetoprololoncytokin elevelsinpatientswithidiopathicdilatedcardiomyopathy[J].AmJCardiol,2002,89(8):9962999.
52 LowesBD,GilbertEM,AbrahamWT,etal.Myocardialgeneindilatedcardiomyopa2thytreatedwithb eta2blockingagents[J].NewEnglJMed,2002,346(18):-135721365.
53 苑海涛,廖玉华,王敏,等.系列抗心肌多肽抗体对扩张型心肌病的诊断价值[J].临床心血管病杂志,2000,16:31-315
54 程龙献,廖玉华,涂源淑,等.扩张型心肌病者血清抗ADP/ATP载体抗体对心肌细胞浆游离钙浓度的影响[J].临床心血管病杂志,1996,11:335-337
55 OsterzielKJ,RankeMB,StrohhmO,etal.Thesomatotrophicsysteminpatientswitdilatedcardiomyop athy:relationofinsulin21ikegrowthfactor21 anditsalterationsdur2inggrowthhorrnonetherapytoc ardiacfunction[J].ClinEndocri,2000,53(1):61268
56 Perrot A,RankeMB,DietzR,etal.Growthhormonetreatrnentindilatedcardiomy2opathy[J].JCardia cSurg,2001,16(2):1272131
57 Jose VJ,ZechariahTU,GeorgeP,etal.Growthhormonetherapyinpatientswithdilatedcardiomyopath y:prelirninaryobservationsofapilotstudy[J].Indi2anHeartJ,1999,51(2):1832185
58 LindeC,lederoqC,Rexs,et aj Long-term benefits of biventricular pacing in congestive heart failure results from the rnultisite stirnulation in cardiorn yopa thy study[J],J Am Coll Cardiol,2002,40(1):111-118
59 EtochS W,C erit oP,HenahanB J,etal.Intermediate 2termresultsafterpartialleftven2triculectomyfor end2stagedilatedcardiomyopathy:isthereasurvivalbenefit?[J].J Cardiac Surg,2001,16(2):1532158
60 DoenstT,Ahn2VeelkenL,SchlensakC,etal.Leftventricularreductionforidiopathdilatedcardiomyo athyasalternativetotransplant2truthordare[J]? ThoracicCadiovascSurg,2001,49(2):70274
61 马鸿斌.曹玉山治疗扩张型心肌病经验[J].中医研究,2000,13(6):6
62 秦国昌.扩张性心肌病治疗报告[J].中国医药学报,1992,(3):32
63 吕承全.樟木生脉饮治疗扩张性心肌病[J].中医研究,1994,(3):25
64 骆丰,邵念方.保丹生脉汤治疗扩张型心肌病心衰30例[J].江苏中医,1997,18(11): 14
65 程继昆,刘庆平.中药治疗扩张型心肌病25例[J].吉林中医药2002,22(1):12
66 郭占军,刘军峰.中西医结合治疗扩张型心肌病6例报道[J].陕西中医学院学报,2002,25(5):19-20
67 郭喜军,王芩,王英.生脉心肌汤治疗扩张型心肌病临床观察[J].北京中医药大学学报,2003,26(1):79
68 商发科.中西医结合治疗扩张型心肌病疗效观察[J].中国中医急症,2003,12(4):300
69 徐伟建,王汉祥,张道亮,等.中西医治疗扩张型心肌病疗效分析[J].上海中医药杂志,2000,11:12-13
70 柳新.运用温阳益气法治疗扩张型心肌病的体会[J].北京中医,2000,4:29
71 吴新欲,陆曙,龚少愚,等.心力神治疗扩张型心肌病的临床观察[J].新中医,2001,33(3):20-21
72 梁贵廷,刘真,于慧卿,等.活力心浓缩水丸治疗扩张型心肌病临床研究[J].河北中医,2002,24(12):883-886
73 柳新,靳军,张勇.自拟温阳益气汤治疗扩张型心肌病86例观察[J].Beijing jouralof TCM,2004,23(6):348
74 史小青,官颖.温阳利水治疗扩张型心脏病心衰32例[J].辽宁中医杂志,2002,29(5):272
75 曾锋自.拟虚里安汤合三联疗法治疗扩张型心肌病心衰32例[J].中国中医药信息杂志,2003,10(7):51
76 肖少寒,邓斌,陈芸,等.中西医结合治疗扩张型心肌病46例临床观察[J].现代医药卫生,2005,21(18):2424-2425
77 田友谊.中药自拟方治疗扩张型心脏病的临床研究[J].Chinese Journal of information on TCM,2005,12(7):54
78 王树炜.心肌复原散治疗扩张型心肌病40例疗效观察[J].四川中医,2004,22(2):48
79 廖蔚茜,房莉萍,丛鹏.益气活血法治疗扩张型心肌病临床观察[J].上海中医药杂志,2005,39(5):临证承启19
80 关德民,张春燕.温阳利水法为主治疗慢性充血性心力衰竭60例[J].中医药学报,2002,30(3):11
81 贺又舜,伍参荣,赵国荣,等.甘露消毒丹对柯萨奇病毒体外抑制作用的实验研究[J].中国中西医结合杂志,1998,18(12):737-740.
82 陈万强,薛成相,马慧,等.中西医结合治疗扩张型心脏病疗效观察[J].西北国防医学杂志,1999,20(4):286-287
83 郑红发.独参汤治疗扩张型心肌病20例疗效观察[J].中国临床药理学与治疗学杂志, 1997,2(1):12
84 刘吉祥,张金艳,冯丽娟,等.中西医结合治疗扩张型心肌病86例临床观察[J].中国新医药,2004,3(3):53-54
85 白玉生,杨晓华,周艳萍.中西医结合治疗扩张型心肌病疗效观察.中西医结合实用临床急救,1997,4(5):216-217
86 梁东勇.加味生脉散配合西药治疗扩张型心肌病30例[J].四川中医,2002,20(4):29-30
87 王西栋,张广兰,梁玉梅,等.小柴胡汤对病毒性心肌炎动物模型治疗作用的实验研究[J].中国中药杂志,1997,22(11):684-686.
88 王雪峰,刘芳,魏克伦,等.小柴胡汤及其分解剂对柯萨奇B3m病毒感染乳鼠心肌保护及细胞免疫调节作用的研究[J].中国中西医结合杂志,2000,20(8):599-602.
89 蒋岩,崔小岱,吴莎,等.红芪提取物(HE)亲心肌柯萨奇B3病毒(CVB3m)感染的作用初探[J].医学研究通讯,1994,23(5):15-18.
90 吴伟忠,杨英珍,金佩英.黄芪对BALb/c小鼠Coxsackie B3病毒T细胞免疫的影响[J].中国病毒学,1992,7(2):129-132.
91 芮涛,杨英珍,杨学义,等.黄芪对小鼠急性病毒性心肌炎作用的心肌细胞电生理研究[J].中国中西医结合杂志,1994,14(5):292-294.
92 郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1995,15(8):483-485.
93 李双杰,张召才,陈瑞珍,等.黄芪甲甙治疗BALB/C小鼠CVB3病毒性心肌炎疗效研究[J].中华实用中西医结合杂志,2004,4(5):681-683.
94 刘晶星,陆德源,杨仲明.苦参抗柯萨奇B组病毒的初步研究[J].上海第二医科大学学报,1991,11(2):140-142.
95 陈福祥,刘晶星,陆德源.苦参总碱体外抗柯萨奇病毒B型3作用测定及其机理的初步研究[J].中华实验和临床病毒学杂志,1995,9(2):115-117.
96 孙非,王秀清,李静波.高山红景天多糖抗柯萨奇B5病毒作用的研究[J].中草药,1993,24(10):532-534.
97 孙非,于起福,孙寒,等.高山红景天多糖对病毒感染大鼠心肌细胞的抑制作用[J].中国药理学通报,1997,13(6):525-528.
98 朱理安.实验性病毒性心肌炎药物治疗及凋亡的机制[J].福建医科大学学报,1998,32(9):318.
99 蒋岩,包天桐,崔小岱,等.薄芝醇提取物体外抗亲心肌柯萨奇B3病毒作用的研究[J].北京中医,1994,(3):31-32.
100 申元英,杨占秋,刘建军,等.大黄在体内抗柯萨奇病毒B3的实验研究[J].中国病毒学, 2001,16(1):85-87.
101 申成华,郑善子,崔春权,等.虎杖水煎液对体外培养柯萨奇病毒B3大鼠心肌细胞保护作用的实验研究[J].中国中医药科技,2005,12(1):34-35.
102 董杰德,陈晨华,仇素英,等.四种中草药抗柯萨奇及埃柯病毒的实验研究[J].山东中医学院学报,1993,17(4):46-48.
103 郑敏,菜飞,吴基良,等.大蒜多醣抗柯萨奇病毒B3及病毒性心肌炎实验研究[J].中华实用中西医结合杂志,2004,4(11):1 577-1579.
104 秦勇,黄方文,王金宇.999参附注射液治疗扩张型心肌病心力衰竭26例[J].辽宁中医杂志,2001,28(7):407
105 阙华星,郭建辉.参附注射液治疗扩张型心肌病32例[J].福建中医药,2003,34(2):17
106 张荣江,安立敏,张连娟,等.参麦注射液与维生素C注射液辅助治疗扩张型心肌病的疗效比较[J].中国新药与临床杂志,2001,20(3):190-192
107 李世光,张启高.参麦注射液治疗扩张型心肌病合并左心功能不全临床观察[J].安徽医药,2002,6(2):27
108 吴新华,焦建玲,施荣杰.生脉注射液辅助治疗扩张型心肌病心力衰竭28例[J].中国中西医结合杂志,200l,21(3):230
109 张亚臣,陈瑞明,赵美华,等.生脉注射液治疗扩张型心肌病心力衰竭的疗效观察[J].临床内科杂志,2002,19(增刊):102-104
110 张兰芹.黄芪和生脉注射液联用治疗扩张型心肌病33例[J].天津中医药,2003,20(2):29
111 徐占兴.复方丹参注射液治疗扩张型心肌病22例疗效分析[J].天津中医药,2003,20(2):74
112 杨桂生.联用当归注射液和复方丹参注射液治疗扩张型心肌病5例[J].中西医结合实用临床急救,1998,5(9):425
113 陈曙霞,包世宏,常佩伦.针刺内关及少府对原发性心肌病心脏效应的初步探索[J].中医杂志,1982,23(8):4852
114 陈曙霞,谢龙山,马睿,等.柯萨奇B病毒性心肌炎、扩张型心肌病中病毒持续感染及中药干预的实验研究[J].中西医结合心脑血管病杂志,2003,1(3):129-131
115 徐伟建,张道亮,李颖,等.保心合剂对CVB3病毒致小鼠慢性心肌损伤的保护作用[J].中西医结合心脑血管病杂志,2006,4(1):39-41
116 Brilla CG,Janick JS,Weber KT.Impaired diastolic function and coronary reserve in genetic hypertension[J].CircRes,1991,69(1):107-109
117 Papoinan T,Lewis W.Selective alterations in rat cardiac mRNA induced bydoxo.rubicin:possiblesubcellular mechanisms.Exp Mol Pathol.1991Apr:54(2):112-21
118 Power JM,Raman J,Byme MJ,et ql.Efficacy of the Acorn Cardiac Support Device in animals with failure secondary to high rate pacing.Heart Fail Rev.2005Jun;10(2):117-23
119 Takagaki M,Meearthy PM,Tobata T,et al.Induction and maintenance of an experimental model of severe cardiomyopathy with a novel protocol of rapid ventricular pacing.J Thorac Cardiomyopa thy with a novel protocol of rapid ventricular pacing.J Thorac Cardiovasc Surg,2002,123(3):544-549
120 McMinn TR,Ross J.Hereditary dilated cardiomyopathy.Clin Cardiol,1998,18(1):7-15
121 TsutamotoT,Wada A,Sakai H,et al.Relationship between renal function and plasma brain natriuretic peptide in patients with heart filure.J Am Coll Cardiol.2006Fbe7;47(3):582-6
122 Ikeda Y,Ross J Models of dilated cardiomyopathy in the mouse and the hamsrer.Curt Opin Cardiol,2000,15(3):197-201
123 Tracy S,Chapman NM,Romero J,et.Genetics of Coxsackievirus B cardioviru-lence and inflammatory heart muscle disease[J].Trends Micr0bil,1996,4:175-179
124 石迪明,陈曙霞,钱福荣,等.扩张型心肌病与病毒持续感染关系的实验研究[J].上海第二医科大学学报,2001,21(3):196-198
125 徐伟建,张道亮,李颖,等.保心合剂对CVB_3病毒致小鼠慢性心肌损伤的保护作用[J].中西医结合心脑血管病杂志,2006,4(1):39-41
126 郭玲,王莹威,孙辉,等.CVB3m重复感染心肌致心室重构的实验研究[J].中国地方病防治杂志,2005,20(3):132-134
127 李双杰,张召才,陈瑞珍,等.Balb/c小鼠CVB3病毒性扩张型心肌病并心力衰竭模型的建立.复旦学报(医学版),2004,31(6):559-561
128 杨英珍,单越芬,赵惠扬,等.黄芪对病毒性心肌炎患者左心室功能的影响[J].上海医科大学学报,1989,16(2):87-91
129 罗海明,戴瑞鸿,李勇.黄芪有效成分治疗充血性心力衰竭的心脏病学研究[J].中国中西医结合杂志,1995,15(12):707-709
130 孙成文,钟国赣,江岩,等.黄芪多糖抗氧化损伤的研究[J].中国药理学通报,1996,12(2):161-163
131 施海明,戴瑞鸿,范维虎.利多卡因和黄芪对心室晚电位的干预作用[J].中国中西医结合杂志,1994,14(10):598-600
132 Guo q,Peng TQ,Yang YZ,et al.Effect of astragalus membranaceus on Ca~(2+)influx and CVB3RNA replication in cultured neonatal rat heart cells infected with CVB3[J].CJIM,1996,2:64-67
133 刘恭鑫,杨英珍,顾全保,等.黄芪对感染病毒大鼠心肌细胞L型离子通道的效应[J]. 中国中西医结合杂忐,1998,18:51-53
134 彭天庆,杨英珍.黄芪对柯萨奇B3病毒核糖核酸作用的研究及其机理探讨[J].中国中西医结合杂志,1994,14(11):664
135 李兰青.地黄药理研究进展[J].中成药,1994,6(9):47.
136 马健,樊巧玲,木村正康.生地黄对“阴虚”模型小鼠腹腔巨噬细胞Ia抗原表面的影响[J].中药药理与临床,1998,14(2):22-24.
137 阿部博子.地黄及八味地黄丸的药效药理[J].国外医学·中医中药分册,1992,14(2):18
138 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,259
139 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,120-121
140 王再谟,傅荣周,唐章全.现代中药临床应用[M].第一版,北京,人民卫生出版社,2005,4,259